China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
ST. LOUIS, April 27, 2017 -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 first quarter ended March 31, 2017 on Monday, May 8, 2017 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis first quarter 2017 financial results conference call |
| When: | Monday, May 8th at 10:00 a.m. Eastern Time (7:00 a.m. PT) |
| Dial In Number: | To access the live call, dial 877-675-4756 (US and Canada) or 719-325-4839 (International) and give the participant pass code 3960816. |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com |
| Call Replay: | A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through Monday, May 15, 2017. To access the replay dial-in information, please click here. |
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
Company Contacts: David L. Fischel Chairman and Acting Chief Executive Officer Martin C. Stammer Chief Financial Officer [email protected]
